IRIS
ARMENI, PATRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.101
NA - Nord America 2.924
AS - Asia 1.141
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 8
AF - Africa 3
Totale 9.200
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.766
IT - Italia 2.363
GB - Regno Unito 771
IE - Irlanda 712
CN - Cina 410
UA - Ucraina 345
DE - Germania 240
SG - Singapore 171
SE - Svezia 158
CA - Canada 149
TR - Turchia 139
FI - Finlandia 128
HK - Hong Kong 109
VN - Vietnam 109
FR - Francia 95
KR - Corea 76
CZ - Repubblica Ceca 58
IN - India 58
BG - Bulgaria 46
BE - Belgio 40
NL - Olanda 38
ES - Italia 20
CH - Svizzera 17
RO - Romania 12
AT - Austria 10
DK - Danimarca 9
IR - Iran 9
EU - Europa 8
PH - Filippine 8
PL - Polonia 8
TW - Taiwan 7
IL - Israele 6
JP - Giappone 6
AU - Australia 4
BR - Brasile 4
JO - Giordania 4
MY - Malesia 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
RU - Federazione Russa 4
SI - Slovenia 4
TH - Thailandia 4
CL - Cile 3
CO - Colombia 3
LV - Lettonia 3
NO - Norvegia 3
PA - Panama 3
PK - Pakistan 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AZ - Azerbaigian 2
BY - Bielorussia 2
BZ - Belize 2
CR - Costa Rica 2
EE - Estonia 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
ID - Indonesia 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
MX - Messico 2
PE - Perù 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AL - Albania 1
AR - Argentina 1
BT - Bhutan 1
KE - Kenya 1
LK - Sri Lanka 1
LT - Lituania 1
OM - Oman 1
SK - Slovacchia (Repubblica Slovacca) 1
SM - San Marino 1
TM - Turkmenistan 1
UG - Uganda 1
ZA - Sudafrica 1
Totale 9.200
Salva come PNG Salva come JPEG
Città #
Dublin 711
Southend 532
Milan 525
Chandler 484
Jacksonville 275
Ann Arbor 234
Rome 190
Toronto 135
Dearborn 128
Singapore 128
Hong Kong 108
Dong Ket 104
New York 97
Beijing 95
Houston 93
Helsinki 84
Wilmington 80
Seoul 75
Modena 66
Lawrence 64
Boston 63
Boardman 62
Izmir 56
Ashburn 52
Naples 44
Redwood City 41
Los Angeles 39
Redmond 39
Brussels 38
Munich 36
Mountain View 34
Woodbridge 33
Bari 30
Casorate Primo 30
Florence 30
Seattle 30
Turin 28
Bologna 24
Catania 24
Hefei 20
Frankfurt am Main 19
Brno 18
Duncan 18
Genoa 18
Nanjing 18
Falkenstein 17
Kunming 17
Dallas 16
London 14
Amsterdam 13
Busto Arsizio 13
Cagliari 13
Palombara Sabina 13
Torino 13
Washington 13
Bonndorf 12
Kocaeli 12
Pisa 12
Paris 11
Boydton 10
Fairfield 10
Melendugno 10
Fremont 9
Guangzhou 9
Jinan 9
Padova 9
Udine 9
Verona 9
Monza 8
Ottawa 8
Palermo 8
Ravenna 8
Prague 7
Warsaw 7
Berlin 6
Bucharest 6
Caserta 6
Casoria 6
Foggia 6
Lappeenranta 6
North Wales 6
Parma 6
Pavia 6
Pescara 6
Pomezia 6
Renton 6
Shanghai 6
Shenyang 6
Taranto 6
Vicenza 6
Vienna 6
Bacoli 5
Bergamo 5
Brescia 5
Carrara 5
Castellalto 5
Fuzhou 5
Gorgonzola 5
Matino 5
Messina 5
Totale 5.518
Salva come PNG Salva come JPEG
Nome #
Digitalizzazione nelle tecnologie per la salute: impatto sui livelli di governo del SSN 391
The cost of patients with chronic kidney failure before dialysis: results from the IRIDE observational study 385
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 298
Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, con un focus sull’adozione di forme alternative di distribuzione dei farmaci 283
La spesa sanitaria: composizione ed evoluzione 261
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 258
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 233
I dispositivi medici in Italia: un settore, tanti mercati 227
Programma Nazionale di HTA per dispositivi medici: prove tecniche di implementazione 176
Il governo regionale dell'assistenza farmaceutica e il suo impatto sulla spesa 166
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 161
L'acquisto di farmaci in Italia: l'effetto di approcci selettivi 161
PHP3 the simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 155
Il governo dell'assistenza farmaceutica in Italia: possibili traiettorie di cambiamento 154
Real-world cost effectiveness of MitraClip combined with medical therapy versus medical therapy alone in patients with moderate or severe mitral regurgitation 150
The impact of HTA and procurement practices on the selection and prices of medical devices 149
Il confronto dei sistemi sanitari in una prospettiva internazionale 145
La rendicontazione e la remunerazione dei farmaci. Finalità, struttura e gestione del File F in nove Regioni italiane 143
Diffusion without evidence: a study on high-risk medical devices 140
Report n. 42 OSFAR (Osservatorio Farmaci) 134
The future of Funds for Innovative Medicines: results from a Delphi Study 133
The impact of generic reference pricing in Italy, a decade on 131
Cost-effectiveness and net monetary benefit of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the Italian National Health Service 131
The impact of generic reference pricing in Italy, a decade on 127
A meta-analysis of MitraClip combined with medical therapy versus medical therapy alone for treatment of mitral regurgitation in heart failure patients 127
La spesa sanitaria: composizione ed evoluzione 126
Market access management by pharmaceutical companies in a complex environment: the Italian case study 125
L'adozione dell'innovazione tecnologica da parte degli ospedali italiani: un'analisi dei fattori endogeni 122
Comparative effectiveness of Mitraclip plus medical therapy versus medical therapy alone in high-risk surgical patients: a comprehensive review 121
Il confronto dei sistemi sanitari in una prospettiva internazionale 119
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 117
When peers count: the effects on integrated type II diabetes care of communication within general practitioner-only subgroups in interprofessional primary care teams 116
Il confronto dei sistemi sanitari in una prospettiva internazionale 116
The social burden and quality of life of patients with haemophilia in Italy 112
Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement) 111
Multi-professional primary care units: what affects the clinical performance of Italian general practitioners? 109
L'attività sperimentale sui dispositivi medici 107
Social/economic costs and quality of life in patients with haemophilia in Europe 107
Il confronto dei sistemi sanitari in una prospettiva internazionale 106
Cost-benefit analysis in health care: the case of bariatric surgery compared with diet 106
Mobile health divide between clinicians and patients in cancer care: results from a cross-sectional international survey 106
La spesa sanitaria: composizione ed evoluzione 103
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 101
A value-based revolution in health care: perspectives, challenges, and emerging approaches to defining and measuring the value of health care technologies 101
La spesa sanitaria: composizione ed evoluzione 100
What type of clinical evidence is needed to assess medical devices? 100
Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe 99
I settori contigui alla sanità: struttura e performance delle imprese farmaceutiche, di dispositivi medici e delle farmacie in Italia 97
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 95
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 94
Social economic costs, health-related quality of life and disability in patients with Cri Du Chat syndrome 93
Il confronto dei sistemi sanitari in una prospettiva internazionale 92
The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study 91
Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis 89
La spesa sanitaria: composizione ed evoluzione 87
Cost-effectiveness and net monetary benefit of Olaparib maintenance therapy versus no maintenance therapy after first-line platinum-based chemotherapy in newly diagnosed advanced BRCA1/2-mutated ovarian cancer in the Italian National Health Service 86
The invisible costs of obstructive sleep apnea (OSA): systematic review and cost-of-illness analysis 85
Cost-utility analysis of esketamine for patients with treatment resistant depression in Italy 85
Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients 84
Digital Twins in healthcare: is it the beginning of a new era of evidence-based medicine? A critical review 81
Implementation of value-based pricing for medicines 81
La spesa sanitaria: composizione ed evoluzione 75
La spesa sanitaria: composizione ed evoluzione 73
La spesa sanitaria: composizione ed evoluzione 70
Variations in non-prescription drug consumption and expenditure: determinants and policy implications 69
La spesa sanitaria: composizione ed evoluzione 68
La spesa sanitaria: composizione ed evoluzione 67
La spesa sanitaria: composizione ed evoluzione 58
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 54
Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case 51
Percutaneous mitral valve repair vs. stand-alone medical therapy in patients with functional mitral regurgitation and heart failure 47
Collecting physicians' preferences on medical devices: are we doing it right? Evidence from Italian orthopedists using 2 different stated preference methods 45
The value of hearing aids for the Italian NHS: a cost-utility analysis 39
Reflections on the importance of cost of illness analysis in rare diseases: a proposal 38
Use of resource modeling to quantify the organizational impact of subcutaneous formulations for the treatment of oncologic patients: the case of daratumumab in multiple myeloma 35
Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention 33
Economic impact of a more extensive use of FENO testing on the Italian population with asthma 28
Individual and team performanc: issues around the role of attributes and relationships among peers 24
Cost-effectiveness analysis of HRD testing for previously treated patients with advanced ovarian cancer in Italy 22
Health system quality and COVID-19 vaccination: a cross-sectional analysis in 14 countries 14
Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe 13
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment 11
Totale 9.423
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.190
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.190
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.290 0 0 0 0 160 193 225 163 183 168 74 124
2020/20211.206 63 88 41 116 121 81 105 60 132 103 108 188
2021/2022935 68 180 36 41 66 12 31 174 41 47 105 134
2022/20232.347 119 127 58 176 153 189 63 101 977 94 165 125
2023/20241.807 104 97 123 89 167 177 105 279 99 136 211 220
2024/2025620 138 36 170 123 153 0 0 0 0 0 0 0
Totale 9.423